ONC offers advice on patient-generated health data

Laura Pedulli | | Health Exec | Precision Medicine

Two new guides released by the Office of the National Coordinator for Health IT (ONC) offer advice on how to navigate the realm of patient-generated health data.

The first guide, “Assessing Patient Experience with Care,” explores the positives of measuring patient experience and highlights practices to achieve this end. Specifically, the guide offers tips on administering patient experience surveys to assess customers’ experiences with health IT like portals, secure messaging and downloading their health information.

The second guide provides fundamental information on patient-generated data, and outlines steps to incorporate such information into medical practices.

View ONC’s website on patient-generated health data here.

 

 

Laura Pedulli

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.